Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Menstrual disorders
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Menstrual disorders
• Abnormal uterine bleeding/ Heavy uterine bleeding
• Amenorrhea• Primary and Secondary
Dysmenorrhea, Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD)
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
ABNORMAL UTERINE BLEEDING
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Abnormal Uterine Bleeding defined as changes in frequency of
menses, duration of flow or amount of blood loss
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Definition of terms
Mean interval between menses is 28 days (±7 days)
Mean duration of menstrual flow is 4 days (>7 days is menorrhagia)
Mean amount of MBL in normal women is about 35 mL (>80 mL is menorrhagia)
DEFINITION OF MENSTRUAL CYCLE IRREGULARITIES: NO LONGER USED
IRREGULARITY DEFINITIONOLIGOMENORRHEA Infrequent IRREGULARLY timed episodes of
bleeding usually occurring at intervals of more than 35 days
POLYMENORRHEA Frequent but REGULARLY timed episodes of bleeding usually occuring at intervals of 21 days or less
MENORRHAGIA REGULARLY timed episodes of bleeding that are EXCESSIVE in amount (> 80 ml) and duration of flow (> 5 days)
METRORRHAGIA Irregularly timed bleeding or bleeding between periods
MENOMETRORRHAGIA
EXCESSIVE, PROLONGED bleeding that occurs at IRREGULARLY timed frequent intervals
HYPOMENORRHEA REGULARLY timed bleeding that is decreased in amount
INTERMENSTRUAL BLEEDING/SPOTTING
Bleeding usually not of an excessive amount that occurs between otherwise normal menstrual cycles
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Etiology
Two major categoriesA. Organic
I. SystemicII. Reproductive Tract disease
B. DysfunctionalI. Anovulatory II. Ovulatory
A. Organic: Systemic Disease• Chronic systemic diseases e.g. hepatitis, renal
disease, cardiac disease, and coronary vascular disorders (usually from anovualtion due to hypothalamic cause or problem with estrogen metabolism)
• Disorders of blood coagulation e.g. von Willebrand's disease and prothrombin deficiency
• Disorders producing platelet deficiency e.g leukemia, severe sepsis, idiopathic thrombocytopenic purpura (ITP), and hypersplenism
• Drugs e.g.anticoagulants • Endocrine disorders e.g. hormonal disorders
involving thyroid, PRL, and cortisol Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
A. Organic: Reproductive Tract Disease The most common cause: accidents of pregnancy Other causes: 1) Malignancy of the genital tract endometrial and cervical cancer – most common vaginal, vulvar, fallopian tube cancer – less common 2) Anatomic uterine abnormalities submucous myomas, endometrial polyps, adenomyosis (probably d/t abnormal vasculature and blood flow and increased inflammatory changes) 3) Cervical lesions erosions, polyps, cervicitis (postcoital bleeding)
ABNORMAL UTERINE BLEEDING: WORKUP
History– Timing of bleeding, quantity of bleeding, menstrual hx
including menarche and recent periods, associated sxs, family hx of bleeding disorders
Physical– Speculum exam to R/o vaginal or cervical source of bleeding– Bimanual exam may reveal bulky uterus/discrete fibroids– Assess for obesity, hirsutism, stigmata of thyroid disease
(hypothyroidism associated with anovulation), signs of hyperprolactinemia (visual field testing, galactorrhea)
– Pap smear– Endometrial biopsy, if appropriate
Pregnancy Test Imaging
– Pelvic ultrasound – Sonohystogram (SIS) or hysterosalpingogram (HSG)
Surgical– Endometrial biopsy (>35 y/o, long history of excessive
bleeding, EM >8mm)– Hysteroscopy– D & CLentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
AUB: TREATMENT STRATEGIES Medical vs Surgical
– Depends on the ff. patient characteristic: age, desire to preserve fertility, coexisting medical conditions, and patient preference
Anovulatory DUB– For adolescents: Cyclic progestogen (MPA 10mg OD for10 days/month x 6 mos) – 1st line COCs – only 2nd line used if DUB persists beyond 6 mos. on cyclic progestogen, because it does not allow HPO to mature– For perimenopausal women: Low dose COCs (20ug EE) – 1st line Cyclic progestogen – only 2nd line, this will help the endometrium but not reliably control bleeding because of unpredictability of the hormonal situationLentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
AUB: TREATMENT STRATEGIES Ovulatory DUB
Cyclic progestogen (MPA 10mg OD for 3 weeks/mo. ) – shorter duration do not workLocal progesterone exposure (LNG-IUS) – 80% MBL by 3 mos (lasts >5 yrs)NSAIDs – Mefenamic acid 500mg TID, Ibuprofen 400mg TID, Meclofenamate Na 100mg TID, Naproxen Na 550mg LD then 275mg q6Antifibrinolytic agents – 50% MBL EACA (ε-aminocaproic acid)18g/d x 3 days then 12g ,9g ,6g, 3g = total 48g AMCA (tranexamic acid) 6/d x 3 days then 4g, 3g, 2g, 1g,= total 22g PAMBA (para-amino methylbenzoic acid)COCs – 50% MBLAndrogenic steroids – Danazol 200-400mg/day x 12 weeks 60% MBL GnRH Agonists – given for 3 months, reserved for women with severe MBL with failed with other medicationLentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
AUB: TREATMENT STRATEGIES Acute Bleeding Pharmacologic Agents vs. Surgical Therapy Dilatation and curettage – fastest way, best when EM is thick >10-12 mm and px is >35 y/o Estrogens – best when EM is thin <5mm Oral CEE 10mg/day in 4 divided doses
IV CEE 25mg q4-6 hrs. High dose OCPs(50ug EE) 4tabs OD, continued for 1week after bleeding stops Progestogens – no evidence in stopping acute bleeding, and can only be used after stabilization of the endometrium (after 2-3 days of estrogen) MPA 10mg/day x 10 days/month Norethindrone acetate 2.5-5mg/day in 4 divided dosesEndometrial ablation – used if medical therapy is not effective 22-55% amenorrhea success rate 86-99% satisfaction rate only 25% proceed to hysterectomy w/in 4 years
Hysterectomy – used to treat persistent ovulatory DUB when medical therapy has failed
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
The “MOST COMMON”• FOREIGN BODY IN
THE VAGINAMost common
cause of vaginal bleeding in CHILDHOOD
• ACCIDENTS OF PREGNANCY
Most common cause of vaginal
bleeding in REPRODUCTIVE
age women
• ATROPHIC ENDOMETRIUM
Most common cause of vaginal
bleeding in POSTMENOPAUSA
L women
Heavy Menstrual BleedingCharacteristics Descriptive
TermsNormal limits
Frequency of menses in days
Frequent Normal
Infrequent
<24 24-38 >38
Regularity of menses in days (cycle to cycle variation in a year)
Absent Regular Irregular
±2-20 >20
Duration of flow in days
Prolonged Normal
Shortened
>8 4.5-8 <4.5
Volume of monthly blood loss in mL
Heavy Normal Light
>80 5-80 <5
Fraser. International definitions of abnormal menstrual bleeding. Fertil Steril 2007 & Hum Reprod 2007
• Chronic AUB– bleeding from the uterine corpus that is
abnormal in volume, regularity, and/or timing that has been present for the majority of the last 6 months
• Acute AUB– episode of heavy bleeding that, in the opinion
of the clinician, is of sufficient severity to require immediate intervention to prevent further blood loss
Abnormal Uterine Bleeding
• Intermenstrual bleeding (IMB)• occurs between clearly defined cyclic and
predictable menses and includes both randomly occurring episodes as well as those that manifest predictably at the same time in each cycle
• Breakthrough bleeding (BTB)• unscheduled bleeding that occurs during
the use of exogenous gonadal steroid therapy
Abnormal Uterine Bleeding
PALM group– discrete structural abnormalities that can be
seen and measured by imaging techniques such as ultrasound or hysteroscopy
COEIN group– non-structural entities, not defined by
imaging or histopathology
Causes of Heavy Menstrual Bleeding
– Polyp– Adenomyosis– Leiomyoma– Malignancy/
Hyperplasia
Causes of Heavy Menstrual Bleeding
*FIGO classification system for causes of abnormal uterine bleeding in the reproductive years
CoagulopathyOvulatory DisordersEndometrial
DisordersIatrogenic CausesNot Classified
PALM COEIN
P olypA denomyosisL eiomyomaM alignancy and
hyperplasia
PALMAUB-P
P olypA denomyosisL eiomyomaMalignancy and
hyperplasia
PALMAUB-A
P olyp
A denomyosis
L eiomyoma
M alignancy and hyperplasia
Submucousal
Other
PALM AUB-LSM
SM - Submucosal
0 Pedunculated intracavitary
(Wamsteker 1993) 1 <50% intramural
2 ≥50% intramuralO - Other Intramural,Subserous, Transmural
3 Contacts endometrium; 100% intramural
4 Intramural5 Subserosal; ≥50%
intramural6 Subserosal; <50%
intramural7 Subserosal
pedunculated8 Other (e.g. cervical,
parasitic)
Leiomyoma Subclassification System
P olypA denomyosisL eiomyomaM alignancy and
hyperplasia
PALM AUB-M
C oagulopathyO vulatory dysfunctionE ndometrialI atrogenicN ot yet classified
COEIN AUB-C
COEIN
C oagulopathyO vulatory dysfunctionE ndometrialI atrogenicN ot yet classified
Causes of Ovulatory Dysfunction
Luteal out of phase cyclesEndocrinopathies
PCOSHypothyroidismHyperprolactinemiaMental stress
ObesityAnorexiaWeight lossExtreme exercise
AUB-O
COEIN
C oagulopathyO vulatory dysfunctionE ndometrialI atrogenicN ot yet classified
Causes of Ovulatory Dysfunction
Systemic Pharmacotherapy Phenothiazines
Tricyclic antidepressants
AUB-O
COEIN
C oagulopathyO vulatory dysfunctionE ndometrialI atrogenicN ot yet classified
Primary disorder of local endometrial hemostasisEndometrial inflammation/infection
Abnormalities in the local inflammatory responseAberrations in endometrial vasculogenesis
AUB-E
COEIN
C oagulopathyO vulatory dysfunctionE ndometrialI atrogenicN ot yet classified
Gonadal Steroids
LNG-IUS
AUB-I
C oagulopathyO vulatory dysfunctionE ndometrialI atrogenicN ot yet classified
Arteriovenous malformationsMyometrial hypertrophyAssociations with some systemic diseasesOthers
COEIN AUB-N
How could this system be used?
– Polyp– Adenomyosis– Leiomyoma– Malignancy/
Hyperplasia
CoagulopathyOvulatory DisordersEndometrial
DisordersIatrogenic CausesNot Classified
PALM COEIN
Heavy menstrual bleeding (HMB) – volume of monthly blood loss of more
than 80 ml– management may be either medical or
surgical
Management of Heavy Menstrual Bleeding
MEDICAL MANAGEMENT SURGICAL MANAGEMENT
Acute HMB Chronic HMB
High dose Estrogen
LNG-IUS Dilatation and curettage
High dose COCs Antifibrinolytic agents
Endometrial ablation
Progestins NSAIDs HysterectomyTranexamic acid COCs
Cyclic progestogenDanazol
Management of Heavy Menstrual Bleeding
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
AMENORRHEA
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Amenorrhea May be physiologic or pathologic which may include
primary and secondary causes Primary amenorrhea. No menses by age 14 in the absence of growth or
development of secondary sexual characteristics. Or No menses by age 16 with the appearance of
secondary sexual characteristics. Secondary amenorrhea.
In a menstruating women, the absence of menstruation for three previous cycle intervals or 6 months.
Evaluation of Amenorrhea
1. History2. Physical examination3. Diagnostics
Diagnostic Evaluation for Secondary Amenorrhea
Causes of Amenorrhea
1. Primary Amenorrhea2. Secondary Amenorrhea
Primary causes initially classified on whether absent uterus and/or breast development are also found
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
AmenorrheaPrimary causes initially classified on whether absent uterus and/or breast development are also found
BREASTS UTERUS CONDITION
ABSENT PRESENT With pituitary massesTURNER’S SYNDROME
PRESENT ABSENT TESTICULAR FEMINIZATION (XY) AND CONGENITAL ABSENCE OF THE UTERUS
ABSENT ABSENT MALE KARYOTYPE EITHER ENZYME DEFICIENCY OR AGONADISM
PRESENT PRESENT HYPOTHALAMIC CAUSES, PITUITARY, OVARIAN, UTERINE OR OUTFLOW TRACT PROBLEMS
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Amenorrhea Secondary amenorrhea may be
physiologic or pathologic. Pathologic lesions include intra-uterine adhesions after curettage. Work up include: HYPOTHALAMIC CAUSES, PITUITARY, OVARIAN, UTERINE OR OUTFLOW TRACT PROBLEMS
Compartmental Systems Compartment I
– Disorders of the outflow tract Compartment II
– Disorders of the ovary Compartment III
– Disorders of the anterior pituitary Compartment IV
– Disorders of CNS (hypothalamic factors)
Compartment I: Disorders of the Outflow Tract or Uterus
Mullerian Anomalies– Imperforate hymen– Transverse vaginal septum
Mullerian agenesis (Mayer-Rokitansky-Kuster-Hauser syndrome)
Androgen insensitivity Ashermans syndrome
Imperforate Hymen•The hymen itself is formed from the proliferation of the sinovaginal bulbs, becoming perforate before or shortly after birth.
•Results when this sheet of tissue fails to completely canalize
•Translucent thin membrane just inferior to the urethral meatus that bulges with valsalva maneuver
Transverse vaginal septum•Horizontal wall of tissue that has formed during embryologic development and essentially creates a blockage in the vagina
• Occurs between the upper one-third and lower two-thirds of the vaginal canal.
•Resection of septum
Mayer-Rokitansky-Kuster-Hauser Syndrome (utero-vaginal agenesis)
15% of primary amenorrhea Normal secondary
development & external female genitalia
Normal female range testosterone level (20-80 ng/dl)
Absent uterus and upper vagina & normal ovaries
Karyotype 46XX 15-30% renal, skeletal and
middle ear anomalies• Treatment: Progressive
vaginal dilatation/vaginoplasty
Androgen Insensitivity Normal breasts but no
sexual hair Normal looking female
external genitalia Absent uterus and upper
vagina Karyotype 46, XY Testes present, male range
testosterone level (300 ng/dL to 800 ng/dL)
Treatment : gonadectomy after puberty + ERT
Androgen Insensitivity(Testicular feminization) 22% with Dysgerminoma or
Gonadoblastoma Gonadectomy once patient
undergoes spontaneous and complete natural breast development
Estrogen monotherapy to prevent osteoporosis and cardiovascular disease
Vaginal dilatation or create neovagina once sexually active
Differences between Mullerian agenesis and Androgen Insensitivity
Mullerian Agenesis Androgen Insensitivity
Karyotype 46, XX 46, XYHeredity Not known Maternal X-linked
recessive; 25% risk of affected child, 25% risk of carrier
Sexual hair Normal female Absent to sparseTestosterone level Normal female Normal to slightly
elevated maleOther anomalies Frequent RareGonadal neoplasia Normal incidence 5% incidence of
malignant tumors
Compartment II: Disorders of the Ovary
Gonadal Dysgenesis Chromosomally abnormal - Classic turner’s syndrome (45XO) - Turner variants (45XO/46XX),(46X-abnormal X) - Mixed gonadal dygenesis (45XO/46XY)
Chromosomally normal - 46XX (Perrault) - 46XY (Swyer’s syndrome)
Gonadal Dysgenesis Gonadal dysgenesis associated with a
normal karyotype is also linked to neurosensory deafness (Perrault syndrome)
Pure gonadal dysgenesis indicates the presence of bilateral streak gonads, regardless of karyotype.
Mixed gonadal dysgenesis indicates testicular tissue on one side and a streak gonad on the other.
Typical features of Turner Syndrome
XY Gonadal Dysgenesis Swyer’s syndrome
– Female patient with XY karyotype– Palpable mullerian system– Normal female testosterone level– Lack of sexual development
Mosaicism Multiple cell lines of varying sex
chromosome composition Appear normal, attaining normal
stature before premature menopause is experienced (accelerated atresia)
Patients are short
Gonadal Agenesis No complicated clinical problems
accompany the gonadal failure due to agenesis
Viral and metabolic influences in early gestation or undiscovered genetic mutations are suspected
Surgical removal of the gonadal streaks is necessary to avoid the possibility of neoplasia
Premature Ovarian Failure Early depletion of ovarian follicles
before the age of 40 Etiology : unknown but maybe due to
genetic disorder with an increased rate of follicle disappearance
Most common abnormalities: 45,X and 47, XXY followed by mosaicism
Hormonal therapy recommended
Radiation
Ovarian dose Sterilization effect
60 rads No effect150 rads Some risk over age 40
250-500 rads Ages 15-40: 60% sterilized
500-800 rads Ages 15-40: 60-70% sterilized
Over 800 rads 100% permanently sterilized
Chemotherapy Alkylating agents – very toxic to the
gonads
Inverse relationship between the dose required for ovarian failure and age at the start of therapy.
Compartment III: Disorders of the Anterior Pituitary
Hypogonadism and delayed puberty warrant brain evaluation by MRI
Nonfunctioning adenoma: microadenoma Pituitary prolactin secreting adenomas Sheehan’s syndrome
– Acute infarction and necrosis of the pituitary gland due to post partum hemorrhage and shock
– Failure of lactation and loss of pubic and axillary hair
Constitutional Delayed Puberty
10-30% of cases with delayed puberty
Physiologic variant in development
Short stature, appropriate bone maturation delay
Delayed secondary sexual characteristics
Familial pattern
Late but otherwise normal growth pattern and adult reproductive function
Compartment IV: Central Nervous System Disorders
Hypothalamic amenorrhea (hypogonadotropic hypogonadism)– Deficiency in GnRH pulsatile secretion– Frequently associated with stress– Higher proportion of underweight
women and previous menstrual irregularity
– Displays the endocrine, metabolic, and psychological characteristics suggesting the presence of a subclinical eating disorder
Compartment IV: Central Nervous System Disorders
– Chronic hypothalamic anovulation Stress Increased exercise levels Anorexia nervosa
– Head trauma– Space-occupying lesions
Exercise and Female Athlete Triad
Disordered eating, amenorrhea, and osteoporosis
↑ endogenous opioids, ACTH, prolactin, adrenal androgens, cortisol, and melatonin
Minimum of 17% body fat required for the initiation of menses and 22% body fat for the maintenance of menses (Frisch. Science 1974)
Exercise and Female Athlete Triad
Low caloric intake during strenuous exercise more important than body fat (Laughlin. J. Clin Endocrinol Metab 1997)
Suboptimal amount of body fat→ estrogens to inactivate catecholestrogens
Stress-induced Hypothalamic Amenorrhea
Potential mediators:– Opioid (β-endorphins)– Dopaminergic (Prolactin)
Activation of H-P-A axis and the stress inhibition of the H-P-G axis
↑ CRF→ ↑ ACTH → ↓ GnRH-LH secretion → ↓steroid biosynthesis
Space-Occupying Lesions Craniopharyngiomas, gliomas,
dermoid cysts Peak incidence: ages 6 and 14 Disruption of tonic inhibition of
dopamine on PRL release Neurological symptoms (headache,
visual field defects) Cranial imaging: Abnormal sella and
calcifications
Kallman’s Syndrome Rare (1:50,000) Autosomal dominant or x-linked
recessive Congenital absence of GnRH
neurons, partial or complete agenesis of olfactory bulb
Sexual infantilism, primary amenorrhea, anosmia
Normal height for their age
Anorexia Nervosa Affects 1-3% of adolescents and young
adults
Diagnostic criteria:– Refusal to maintain body weight at or above
normal weight for height and age– Intense fear of gaining weight or being fat, even
though underweight– Denial of seriousness of current low body weight– Amenorrhea
Anorexia Nervosa Restrictive Type
– W eight is mainly controlled by restricting oral intake
B inge-eating/Purging subtype– Self-induced vomiting– Misuse of laxative
Anorexia Nervosa (Physical examination)
B radycardia, hypothermia, abnormal response to heat and cold
Dry skin, yellow skin (hypercarotenemia) Scaphoid abdomen, loss of subcutaneous
fat Submandibular adenopathy or parotid
gland enlargement Cardiac murmur Prepubertal appearing vaginal mucosa
(hypoestrogenemia)
Anorexia Nervosa (Laboratory Findings)
Low Normal HighFSH TSH Serum total
cortisol
LH Prolactin Serum free cortisol
Estradiol ACTH 24 hour urinary free cortisol
Leptin
IGF-I
DHEAS
Anorexia Nervosa and Leptin Ideal sensor of energy deficiency Concentration increases with obesity
and decreases rapidly during fasting Regulates the synthesis and
secretion of GnRH, gonadotropins, and sex steroids
Low leptin levels in anorexia nervosa significantly correlated with low IGF-I levels
Anorexia Nervosa and Skeletal System
Decreased bone formation and increased resorption → increased rates of osteopenia and osteoporosis
44-92% patients with osteopenia with amenorrhea of < 24 months
Normalization of B MD with weight recovery noted in some cross-sectional studies
Anorexia Nervosa and Skeletal System
Osteopenia improves but does not resolve with weight gain in recent prospective studies
OC and recombinant human IGF-I with significant positive effect on B MD
Hypothalamic Amenorrhea (Hypothalamic hypogonadism)
Most common cause of primary and secondary amenorrhea
Abnormalities of GnRH secretion and disruption of H-P-O axis
Low levels of FSH, LH, estrogen
Diagnosis by exclusion of pituitary lesions
Hypothalamic Amenorrhea (Hypogonadotropic hypogonadism)
Mild suppression: marginal effect on reproduction, inadequate luteal phase
Moderate suppression: anovulation with menstrual irregularity
Profound suppression: Hypothalamic amenorrhea– W eight loss, exercise, stress
Hypothalamic Amenorrhea (Hypogonadotropic hypogonadism)
83% resumed menses once precipitating cause of amenorrhea is reversed(Perkins et al. Hum Reprod 16: 2198, 2001)
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
The “MOST COMMON”• ANOREXIA NERVOSA
Most common cause of
amenorrhea in adolescents
• GONADAL FAILUREMost common
cause of PRIMARY
amenorrhe
• SERUM FSHTest to confirm gonadal failure
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
DYSMENORRHEA
Dysmenorrhea Primary Dysmenorrhea – pain with no obvious pathologic
disease (usually <20 y.o) Secondary Dysmenorrhea – associated with pelvic
conditions or pathology causing pelvic pain in conjunction with menses (most often >20 y/o)
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
CAUSES OF SECONDARY DYSMENORRHEAGynecologic Pathology Non-gynecologic
Disorders Causing Pelvic Pain
Cervical stenosis Endometriosis and adenomyosis Pelvic infection and adhesions Uterine polyps or fibroids Ovarian cyst or mass Pelvic congestion Congenital obstructed mullerian malformations
Conditioned behavior Bowel disease Irritable bowel syndrome Inflammatory bowel disease Celiac sprue (?) Lactose intolerance (?)Urinary tract disease Ureteral obstruction Interstitial cystitis Nephrolithiasis
Differences between Primary and Secondary DysmenorrheaPrimary Dysmenorrhea Secondary
DysmenorrheaCause Effects of endogenous prostaglandin Secondary to pelvic pathology
Hx Midline crampy lower abdominal pain w/c gradually resolves over 12-72 hrs and does not occur at times other than menses
Pain not responding to NSAIDs and OCsOccur after many years of painless menses
Associated symptom
DiarrheaHeadacheFatigue or Malaise
+/- Urinary and Bowel symptoms
PE Normal pelvic examAdolescents with dysmenorrhea in first 6 months of menarche – consider obstructive genital tract malformation
(+) physical finding associated with: cervical stenosis, endometriosis, adenomyosis, fibroids, ovarian cyst, nongynecologic disorders (bowel disease or urinary tract disease)
Treatment
NSAIDs (Fenamates>ibuprofen, naproxen, indomethacin)COX-2 inhibitorsOCs, LNG-IUS, TENS, Nifedipine, Narcotic analgesic - last resort
Treat underlying disease
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Primary Dysmenorrhea: Pathogenesis
Arachidonic acid PGF2α uterine hypercontractility uterine blood flow Ischemia Sensitization of pain fibers
Endometrial PGF2α and PGE2 correlates with severity of dysmenorrhea and may affect other organs (bowel causing N/V and diarrhea)
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
PREMENSTRUAL DISORDERS:
Premenstrual Syndrome (PMS) Premenstrual Dysphoric Disorder (PMDD)
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Premenstrual Disorders: PMS and PMDD
Premenstrual Syndrome (PMS)
Premenstrual Disphoric Disorder (PMDD)
Definition is defined as a group of mild to moderate symptoms, physical and behavioral, that occur in the 2nd half of the menstrual cycle and that may interfere with work and personal relationships, followed by an entirely symptom-free period.
represents a more severe disease, with marked behavioral and emotional symptoms.
Similarity Manifest in the LUTEAL PHASE of menstrual cycle Resolve during menses
Differences
Severity of symptomMust have one severe affective symptom which occur regularly during the last week of the luteal phase:Markedly depressed mood or hopelessnessAnxiety or tensionAffective labilityPersistent anger5 of 11 symptom in the DSM-IV criteria
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Key symptoms of PMS AND PMDD
Somatic symptoms Affective symptoms
Abdominal bloating, swelling, weight gain Aches Increased appetite, food cravings Breast pain or tendernessHeadache Dizziness, poor coordination, clumsiness Cramps, change in bowel habits Fatigue
Depressed mood+ Irritability, persistent anger+
Mood lability, crying, social withdrawal+ Anxiety, tension+ Feeling hopeless or guilty Poor impulse control or feeling out of control Decreased interest, change in libido Insomnia Loss of concentration, confusion+ being severe before menstruation starts and mild or absent after menstruation
Severe PMS or PMDD is based on at least five symptoms, including one of four core psychological symptoms
Modified from the American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision (DSM-IV-TR). Washington, DC, 2000, American Psychiatric
Association, pp. 771-774.
Premenstrual Disorders: PMS and PMDD
Lentz GM, Lobo RA, Gershenson DM, and Katz VL. Comprehensive Gynecology 2012. 6th Edition.
Premenstrual Disorders: PMS and PMDD
PROPOSED CAUSES OF PMS AND PMDD
In summary, the cause of PMS and PMDD is associated with ovarian steroids and ovulation, which seems to produce alterations in neurohormones and neurotransmitters that lead to a reduction of serotonergic function during the luteal phase. Beta-endorphin, GABA, the autonomic nervous system, and social expectations may also play a role in these complex disorders.
Premenstrual Disorders: PMS and PMDDPremenstrual Syndrome
(PMS)Premenstrual Disphoric Disorder
(PMDD)Diagnosis Made by history of 2 consecutive menstrual cycles demonstrating luteal phase symptoms
Medical problems influencing symptomatology must be ruled out (by history and PE)
Differential Diagnosis
Endometriosis Dysmenorrhea Physical disorders with premenstrual exacerbations Autoimmune disordersDiabetes mellitus Anemia
Hypothyroidism Psychiatric disorders with luteal phase exacerbation DepressionAnxiety Dysthymic disorder Bipolar disorder
Treatment
1. Diet, Exercise, and Lifestyle Changes - complex CHO diet (tryptophan as source of serotonin), low fat vegetable diet (SHBG to decrease active estrogen), high-intensity aerobic exercise, Calcium (1200mg/day x 3 months), Vit B6 (50mg/d), Mg (200-400mg/d)
2. Cognitive Behavioral Therapy – less effective as primary therapy, usually as supportive adjunct to managing symptoms of PMS through group psychoeducation and relaxation therapy
3. Pharmacologic agents Diuretics – for bloating, fluid retention and perceived change in body habitus; use K-sparing diuretic (Spirinolactone 100mg/d) Psychoactive drugs – SSRIs are extremely effective (luteal phase or continuous) – caution if px has anxiety symptoms (FDA approved for PMDD: Fluoxetine HCl/Sarafem 20mg/d, Sertraline HCl/Zoloft 50mg/d, Paroxetine HCl/ Paxil CR 12.5mg/d); Alprazolam 025mg TID Day 20-28/cycle; Buspirinone less addictive potential vs Alprazolam Oral Contraceptives – mainly for physical symptoms: breast pain, bloating, acne, and appetite. (Monophasic OCs with shortened hormone-free interval (3-4 days) – better; FDA approved for PMDD: Ethinyl estradiol 20 ug, drosperinone 3mg/ YAZ NSAIDs – for cramping and other systemic symptoms (i.e. aches, diarrhea, or heat intolerance) Danazol – for premenstrual mastalgia 200mg/day Day 20-28/cycle Bromocriptine – for cyclic mastalgia at 2.5-5 mg/day during the luteal phase GnRH agonists – ovulation suppression, treatment of PMS and physical symptoms of PMDD4. Surgical Treatment: Total Hysterectomy and Bilateral oophorectomy – if all other
treatment regimens have failed.
Thank you !